CALGARY, Oct. 19 /CNW/ - SemBioSys Genetics Inc. (the “Company”) (TSX:SBS), a biotechnology company developing a portfolio of therapeutic proteins for metabolic and cardiovascular diseases, today announced that it has agreed to increase the underwriters’ option to acquire additional Units (as described below) from 375,000 Units to 1,180,000 Units on the same terms as previously announced, at a price of $2.60 per Unit. If the underwriters exercise the option to acquire additional Units in full, the size of the offering will be increased from 2,500,000 Units to 3,680,000 Units and the total gross proceeds to the Company will be increased from $6,500,000 to $9,568,000.
